Although the risk of anti-TNF-α-induced cancer for autoimmune patients is still debated, it provides a good example of a situation in which promoting tolerance via TNFR2 targeting would presumably be a better strategy than targeting TNF-α. Here, TNFRSF1B is linked to cancer.